Baseline Characteristics and Preliminary Safety from a Multicenter, Safety Surveillance Study of Lecanemab Treatment for Alzheimer’s Disease in Real-world Clinical Practice Using Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) Registry

Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance – Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials